NCT02115282 2025-12-18
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
Hoffmann-La Roche
National Cancer Institute (NCI)
Syndax Pharmaceuticals
University of Maryland, Baltimore
National Institutes of Health Clinical Center (CC)